bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.04.24.720629

DxFit: An ensemble method for identifying EHR diagnoses consistent with a molecular finding

Torene, R. I.·Meltz Murphy, K.·Brandt, T.·Retterer, K.
View original source ↗Export metadata ↓

Abstract

As population DNA sequencing becomes more common, genomic-first approaches are increasingly used to identify individuals with possible rare genetic disorders. To accurately estimate prevalence and penetrance, these studies often confirm manifestation of the disorder using electronic health records (EHRs). Multiple strategies exist to search the EHR for diagnoses of rare disorders, however, each has its limitations. We have developed a portable, ensemble tool, DxFit, that mines EHR data (ICD codes and structured diagnosis descriptions from billing code and problem list tables) for a diagnosis consistent with a given rare genetic disorder. DxFit combines evidence across four strategies: (1) gene name searches in diagnosis descriptions and notes, (2) ICD conversion to Mondo rare disorder ontology to find exact and nearby matches, (3) word embedding similarity searches, and (4) Jaccard similarity matches. DxFit prioritizes the match type and outputs the most confident match for each participant-disorder pair. On a cohort of 350 participants with a known positive result from diagnostic genetic testing for developmental disorders, DxFit had a sensitivity of 88.7% and specificity of 86.2% using default parameters. Adjusting the linguistic scoring thresholds from 0.8 to 0.7 and allowing for synonymous matches yielded a sensitivity of 92.7% and specificity of 84.5%. Partitioning EHR evidence into windows before and after genetic testing demonstrates, as expected, that the overall DxFit rates increase after testing and the match types become more confident. DxFit is available to the public and has extensive customization options to support a wide range of uses. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=187 HEIGHT=200 SRC="FIGDIR/small/720629v1_ufig1.gif" ALT="Figure 1"> View larger version (41K): org.highwire.dtl.DTLVardef@d71d00org.highwire.dtl.DTLVardef@b11a9eorg.highwire.dtl.DTLVardef@14a9304org.highwire.dtl.DTLVardef@fa23aa_HPS_FORMAT_FIGEXP M_FIG C_FIG

Explore related subjects

genomicsPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Torene, R. I., Meltz Murphy, K., Brandt, T., Retterer, K.. 2026-04-28. DxFit: An ensemble method for identifying EHR diagnoses consistent with a molecular finding. https://doi.org/10.64898/2026.04.24.720629

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

PfPHAST: Plasmodium falciparum Public Health Amplicon Sequencing Tool, a Streamlined Panel for Malaria Genomic Surveillance

Genomic tools can support malaria control policy through surveillance of Plasmodium falciparum populations, tracking antimalarial drug resistance, pfhrp2/3 deletions that compromise rapid diagnostic tests, and selection at the circumsporozoite protein (PfCSP) vaccine target, as well as through molecular correction of therapeutic efficacy studies (TES). Multiplex Amplicons for Drug, Diagnostic, Diversity, and Differentiation Haplotypes using Targeted Resequencing (MAD4HatTeR), a comprehensive amplicon sequencing panel covering up to 276 targets, supports these applications but is tailored to research rather than routine programmatic use. We developed P. falciparum Public Health Amplicon Sequencing Tool (PfPHAST), a 56-target derivative of MAD4HatTeR spanning drug resistance loci, pfhrp2/3 deletion, PfCSP genotyping, non-falciparum species identification, and 20 high-heterozygosity microhaplotype loci for TES classification. We compared PfPHAST and MAD4HatTeR using laboratory strain controls, including two-strain dilution series and a five-strain mixture, across parasite densities of 100 to 10,000 parasites/L. At matched per-target depth, PfPHAST achieved a higher quality-control pass rate than MAD4HatTeR (94.4% versus 90.0%) and distributed reads more evenly across targets. The panels showed comparable recall and precision for drug resistance codons and microhaplotypes, reaching near-complete recall above 40% within-sample allele frequency (WSAF) at all densities, with reduced sensitivity for minor alleles below 10% WSAF at low parasite density in both panels. Observed and expected WSAF correlated strongly for both panels, and both resolved a five-strain polyclonal mixture, including a 5% minor strain. By concentrating sequencing capacity on targets of greatest programmatic relevance, PfPHAST offers a scalable, lower-cost alternative to comprehensive research panels without sacrificing performance on shared targets, complementing MAD4HatTeR for routine molecular malaria surveillance.

genomics↗
bioRxiv2026

Structural variation in repeat elements is widespread in normal human tissues and in tumorigenesis

Somatic mosaicism contributes to genomic variation, yet postzygotic structural variants remain under-characterized. We performed long- and short-read WGS from multiple individuals (n=47 normal tissues; n=168 samples) and identified mosaic structural variants in all individuals and germ layers, impacting a median 285.2 kb/genome. Nearly half of breakpoints were independently validated, with tissue distributions reflecting both early and late developmental origins. Most mosaic variants were repeat-mediated and 8.3% overlapped functional elements, an enrichment compared to germline variants. To extend these analyses in samples where long-read sequencing is infeasible, we measured repeat alterations from short-read sequencing, recapitulating mosaic tissue-specific differences. We characterized tumor- and tissue- specific variation in repeats across 15 cancer types and found tumor-related repeat variation to be similar in scale to that of normal mosaic variation. Tracking repeat changes in cell-free DNA provided a noninvasive approach for tumor monitoring. Our analyses revealed widespread repeat-driven structural variation in health and disease.

genomics↗
bioRxiv2026

RNA isoform-resolved multiplexed sequencing with bioorthogonal barcoding

RNA isoform dysregulation drives disease pathogenesis and is the target of FDA-approved splice-switching therapeutics. However, multiplexed sequencing methods discard splice junction information because only 3' termini are barcoded and counted. Here, we repurpose acylation and click chemistries to conjugate bioorthogonal barcodes (bobcodes) directly onto multiple internal positions along cellular RNAs. Bobcoded RNAs from multiple samples are pooled for multiplexed cDNA synthesis, during which reverse transcriptase switches from each RNA template onto its tethered bobcode with greater than 99% accuracy in species mixing experiments. Bobcode attachment intervals set cDNA insert sizes without a library fragmentation step, and priming with poly(dT) or random hexamers selects between 3'-end counting and full-length isoform capture. A bioorthogonal barcode-sequencing (BOB-seq v0.1) drug screen identifies transcriptome-wide on- and off-target RNA splicing effects and outperforms existing multiplexing RNA sequencing methods in workflow simplicity, sample-to-sample variability, and barcoding accuracy. Bobcodes add isoform resolution to scalable multiplexed RNA sequencing.

genomics↗